{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:51:42Z","timestamp":1791269502613,"version":"4.1.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["111-2536-319\/2K23\/1"],"award-info":[{"award-number":["111-2536-319\/2K23\/1"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ICMR ad hoc","award":["5\/8-4\/15\/Env\/2020-NCD-II"],"award-info":[{"award-number":["5\/8-4\/15\/Env\/2020-NCD-II"]}]},{"name":"ASEAN-India Collaborative R&D Scheme","award":["CRD\/2024\/000898"],"award-info":[{"award-number":["CRD\/2024\/000898"]}]},{"name":"ANRF-IRG Scheme","award":["ANRF\/IRG\/2024\/001655\/LS"],"award-info":[{"award-number":["ANRF\/IRG\/2024\/001655\/LS"]}]},{"name":"CMRG Scheme","award":["CMRG\/3005\/H3\/2024\/080"],"award-info":[{"award-number":["CMRG\/3005\/H3\/2024\/080"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-025-11416-y","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:03:55Z","timestamp":1765443835000},"page":"6651-6675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological effect of quinazoline-2,4(1H,3H)-dione derivatives: a review"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9777-4242","authenticated-orcid":false,"given":"Suryaa","family":"Manoharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2159-8198","authenticated-orcid":false,"given":"Ekambaram","family":"Perumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"11416_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10593-012-0960-z","volume":"48","author":"A Gomtsyan","year":"2012","unstructured":"Gomtsyan A (2012) Heterocycles in drugs and drug discovery. Chem Heterocycl Compd (N Y) 48:7\u201310. https:\/\/doi.org\/10.1007\/s10593-012-0960-z","journal-title":"Chem Heterocycl Compd (N Y)"},{"key":"11416_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3390\/molecules25081909","volume":"25","author":"N Kerru","year":"2020","unstructured":"Kerru N, Gummidi L, Maddila S et al (2020) A review on recent advances in nitrogen-containing molecules and their biological applications. Molecules 25:1909. https:\/\/doi.org\/10.3390\/molecules25081909","journal-title":"Molecules"},{"key":"11416_CR3","doi-asserted-by":"publisher","first-page":"10257","DOI":"10.1021\/jm501100b","volume":"57","author":"E Vitaku","year":"2014","unstructured":"Vitaku E, Smith DT, Njardarson JT (2014) Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA Approv Pharmaceuticals J Med Chem 57:10257\u201310274. https:\/\/doi.org\/10.1021\/jm501100b","journal-title":"FDA Approv Pharmaceuticals J Med Chem"},{"key":"11416_CR4","doi-asserted-by":"publisher","first-page":"11622","DOI":"10.1021\/acs.jmedchem.4c01122","volume":"67","author":"CM Marshall","year":"2024","unstructured":"Marshall CM, Federice JG, Bell CN et al (2024) An update on the nitrogen heterocycle compositions and properties of U.S. FDA-approved pharmaceuticals (2013\u20132023). J Med Chem 67:11622\u201311655. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01122","journal-title":"J Med Chem"},{"key":"11416_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113218","volume":"214","author":"S Wang","year":"2021","unstructured":"Wang S, Yuan X-H, Wang S-Q et al (2021) FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: synthesis and clinical application. Eur J Med Chem 214:113218. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113218","journal-title":"Eur J Med Chem"},{"key":"11416_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113016","volume":"211","author":"R Bansal","year":"2021","unstructured":"Bansal R, Malhotra A (2021) Therapeutic progression of quinazolines as targeted chemotherapeutic agents. Eur J Med Chem 211:113016. https:\/\/doi.org\/10.1016\/j.ejmech.2020.113016","journal-title":"Eur J Med Chem"},{"issue":"1","key":"11416_CR7","first-page":"1","volume":"1","author":"TP Selvam","year":"2015","unstructured":"Selvam TP, Kumar PV (2015) Quinazoline marketed drugs\u2014a review. Res Pharm 1(1):1\u201321","journal-title":"Res Pharm"},{"key":"11416_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cbdv.200490173","volume":"2","author":"I Lagoja","year":"2005","unstructured":"Lagoja I (2005) Pyrimidine as constituent of natural biologically active compounds. Chem Biodivers 2:1\u201350. https:\/\/doi.org\/10.1002\/cbdv.200490173","journal-title":"Chem Biodivers"},{"key":"11416_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/90700609","volume":"9","author":"IA Rivero","year":"2004","unstructured":"Rivero IA, Espinoza K, Somanathan R (2004) Syntheses of quinazoline-2,4-dione alkaloids and analogues from Mexican Zanthoxylum Species \u2020. Molecules 9:609\u2013616. https:\/\/doi.org\/10.3390\/90700609","journal-title":"Molecules"},{"key":"11416_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/med.21466","volume":"38","author":"X Shang","year":"2018","unstructured":"Shang X, Morris\u2010Natschke SL, Liu Y et al (2018) Biologically active quinoline and quinazoline alkaloids part I. Med Res Rev 38:775\u2013828. https:\/\/doi.org\/10.1002\/med.21466","journal-title":"Med Res Rev"},{"key":"11416_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.scp.2022.100696","volume":"27","author":"D Gheidari","year":"2022","unstructured":"Gheidari D, Mehrdad M, Maleki S (2022) The quinazoline-2,4(1H,3H)-diones skeleton: a key intermediate in drug synthesis. Sustain Chem Pharm 27:100696. https:\/\/doi.org\/10.1016\/j.scp.2022.100696","journal-title":"Sustain Chem Pharm"},{"key":"11416_CR12","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1021\/je2004929","volume":"56","author":"MS Miranda","year":"2011","unstructured":"Miranda MS, Matos MAR, Morais VMF, Liebman JF (2011) Energetics of quinazoline-2,4(1 H,3 H )-dione: an experimental and computational study. J Chem Eng Data 56:4516\u20134523. https:\/\/doi.org\/10.1021\/je2004929","journal-title":"J Chem Eng Data"},{"key":"11416_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108304","volume":"157","author":"S Manoharan","year":"2025","unstructured":"Manoharan S, Murugesan K, Gunasekaran S et al (2025) Quinazoline-2,4(1H,3H)-dione modulates STAT3 and FOXO3a signaling in HepG2 cells. Bioorg Chem 157:108304. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108304","journal-title":"Bioorg Chem"},{"key":"11416_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/aoc.6631","author":"D Gheidari","year":"2022","unstructured":"Gheidari D, Mehrdad M, Maleki S (2022) Recent advances in synthesis of quinazoline-2,4(1H,3H )-diones: Versatile building blocks in N -heterocyclic compounds. Appl Organomet Chem. https:\/\/doi.org\/10.1002\/aoc.6631","journal-title":"Appl Organomet Chem"},{"key":"11416_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.ejmech.2018.03.076","volume":"151","author":"V Alagarsamy","year":"2018","unstructured":"Alagarsamy V, Chitra K, Saravanan G et al (2018) An overview of quinazolines: pharmacological significance and recent developments. Eur J Med Chem 151:628\u2013685. https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.076","journal-title":"Eur J Med Chem"},{"key":"11416_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/cbdd.14129","volume":"100","author":"HAM Gomaa","year":"2022","unstructured":"Gomaa HAM (2022) A comprehensive review of recent advances in the biological activities of quinazolines. Chem Biol Drug Des 100:639\u2013655. https:\/\/doi.org\/10.1111\/cbdd.14129","journal-title":"Chem Biol Drug Des"},{"key":"11416_CR17","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1007\/s00044-024-03318-9","volume":"33","author":"IA Bala","year":"2024","unstructured":"Bala IA, Asiri AM, El-Shishtawy RM (2024) Quinazoline derivatives and hybrids: recent structures with potent bioactivity. Med Chem Res 33:2372\u20132419. https:\/\/doi.org\/10.1007\/s00044-024-03318-9","journal-title":"Med Chem Res"},{"key":"11416_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202400057","author":"MM Ghoneim","year":"2024","unstructured":"Ghoneim MM, Abdelgawad MA, Elkanzi NAA et al (2024) A literature review on pharmacological aspects, docking studies, and synthetic approaches of quinazoline and quinazolinone derivatives. Arch Pharm Weinheim. https:\/\/doi.org\/10.1002\/ardp.202400057","journal-title":"Arch Pharm Weinheim"},{"key":"11416_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11030-012-9421-y","volume":"17","author":"X Zhou","year":"2013","unstructured":"Zhou X, Xie X, Liu G (2013) Quinazoline-2,4( $$1H,3H$$ )-diones inhibit the growth of multiple human tumor cell lines. Mol Divers 17:197\u2013219. https:\/\/doi.org\/10.1007\/s11030-012-9421-y","journal-title":"Mol Divers"},{"key":"11416_CR20","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1039\/C7CS00082K","volume":"46","author":"T Mathew","year":"2017","unstructured":"Mathew T, Papp A\u00c1, Paknia F et al (2017) Benzodiazines: recent synthetic advances. Chem Soc Rev 46:3060\u20133094. https:\/\/doi.org\/10.1039\/C7CS00082K","journal-title":"Chem Soc Rev"},{"key":"11416_CR21","first-page":"279","volume-title":"Progress in heterocyclic chemistry","author":"GHC Woo","year":"2002","unstructured":"Woo GHC, Snyder JK, Wan Z-K (2002) Chapter 6.2 Six-membered ring systems: Diazines and benzo derivatives. Progress in heterocyclic chemistry. Elsevier, Netherlands, pp 279\u2013309"},{"key":"11416_CR22","first-page":"1","volume-title":"Comprehensive Heterocyclic Chemistry","author":"M Ti\u0161ler","year":"1984","unstructured":"Ti\u0161ler M, Stanovnik B (1984) Pyridazines and their Benzo Derivatives. Comprehensive Heterocyclic Chemistry. Elsevier, Netherlands, pp 1\u201356"},{"key":"11416_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/395637","volume":"2014","author":"M Asif","year":"2014","unstructured":"Asif M (2014) Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives. Int J Med Chem 2014:1\u201327. https:\/\/doi.org\/10.1155\/2014\/395637","journal-title":"Int J Med Chem"},{"key":"11416_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113949","volume":"227","author":"Z Haghighijoo","year":"2022","unstructured":"Haghighijoo Z, Zamani L, Moosavi F, Emami S (2022) Therapeutic potential of quinazoline derivatives for Alzheimer\u2019s disease: a comprehensive review. Eur J Med Chem 227:113949. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113949","journal-title":"Eur J Med Chem"},{"key":"11416_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1752-153X-7-95","volume":"7","author":"D Wang","year":"2013","unstructured":"Wang D, Gao F (2013) Quinazoline derivatives: synthesis and bioactivities. Chem Cent J 7:95. https:\/\/doi.org\/10.1186\/1752-153X-7-95","journal-title":"Chem Cent J"},{"key":"11416_CR26","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1055\/s-2007-983808","volume":"2007","author":"T Mizuno","year":"2007","unstructured":"Mizuno T, Mihara M, Nakai T et al (2007) Solvent-free synthesis of quinazoline-2,4(1 H ,3 H )-diones using carbon dioxide and a catalytic amount of DBU. Synthesis 2007:2524\u20132528. https:\/\/doi.org\/10.1055\/s-2007-983808","journal-title":"Synthesis"},{"key":"11416_CR27","unstructured":"pubchem.ncbi.nlm.nih.gov PubChem. https:\/\/pubchem.ncbi.nlm.nih.gov\/. [Accessed 1 Dec 2024]"},{"key":"11416_CR28","doi-asserted-by":"publisher","first-page":"o1677","DOI":"10.1107\/S1600536808024240","volume":"64","author":"G Liu","year":"2008","unstructured":"Liu G (2008) Quinazoline-2,4(1 H,3 H )-dione. Acta Crystallogr Sect E Struct Rep Online 64:o1677\u2013o1677. https:\/\/doi.org\/10.1107\/S1600536808024240","journal-title":"Acta Crystallogr Sect E Struct Rep Online"},{"key":"11416_CR29","unstructured":"Gaudilliere BHJJPMW (2005) Alkynylated fused ring pyrimidine compounds"},{"key":"11416_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133263","volume":"14","author":"S Li","year":"2022","unstructured":"Li S, Pritchard DM, Yu L-G (2022) Regulation and function of matrix metalloproteinase-13 in cancer progression and metastasis. Cancers (Basel) 14:3263. https:\/\/doi.org\/10.3390\/cancers14133263","journal-title":"Cancers (Basel)"},{"key":"11416_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0968-0896(01)00299-1","volume":"10","author":"H-Y Park Choo","year":"2002","unstructured":"Park Choo H-Y, Kim M, Lee SK et al (2002) Solid-phase combinatorial synthesis and cytotoxicity of 3-aryl-2,4-quinazolindiones. Bioorg Med Chem 10:517\u2013523. https:\/\/doi.org\/10.1016\/S0968-0896(01)00299-1","journal-title":"Bioorg Med Chem"},{"key":"11416_CR32","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1158\/1535-7163.MCT-12-1176-T","volume":"12","author":"A De Robertis","year":"2013","unstructured":"De Robertis A, Valensin S, Rossi M et al (2013) Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells. Mol Cancer Ther 12:1180\u20131189. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1176-T","journal-title":"Mol Cancer Ther"},{"key":"11416_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097847","volume":"9","author":"A De Robertis","year":"2014","unstructured":"De Robertis A, Mennillo F, Rossi M et al (2014) Human sarcoma growth is sensitive to small-molecule mediated AXIN stabilization. PLoS ONE 9:e97847. https:\/\/doi.org\/10.1371\/journal.pone.0097847","journal-title":"PLoS ONE"},{"key":"11416_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J et al (2022) Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther 7:3. https:\/\/doi.org\/10.1038\/s41392-021-00762-6","journal-title":"Signal Transduct Target Ther"},{"key":"11416_CR35","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M (2017) Wnt signaling in cancer. Oncogene 36:1461\u20131473. https:\/\/doi.org\/10.1038\/onc.2016.304","journal-title":"Oncogene"},{"key":"11416_CR36","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/sj.emboj.7601592","volume":"26","author":"N Bhutani","year":"2007","unstructured":"Bhutani N, Venkatraman P, Goldberg AL (2007) Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polyglutamine sequences released by proteasomes during protein degradation. EMBO J 26:1385\u20131396. https:\/\/doi.org\/10.1038\/sj.emboj.7601592","journal-title":"EMBO J"},{"key":"11416_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287086","volume":"18","author":"S Madabushi","year":"2023","unstructured":"Madabushi S, Chow KM, Song ES et al (2023) Structure of puromycin-sensitive aminopeptidase and polyglutamine binding. PLoS ONE 18:e0287086. https:\/\/doi.org\/10.1371\/journal.pone.0287086","journal-title":"PLoS ONE"},{"key":"11416_CR38","doi-asserted-by":"publisher","first-page":"530","DOI":"10.4014\/jmb.0807.438","volume":"19","author":"SH Lee","year":"2009","unstructured":"Lee SH (2009) Cobalt chloride-induced downregulation of puromycin-sensitive aminopeptidase suppresses the migration and invasion of PC-3 cells. J Microbiol Biotechnol 19:530\u2013536. https:\/\/doi.org\/10.4014\/jmb.0807.438","journal-title":"J Microbiol Biotechnol"},{"key":"11416_CR39","doi-asserted-by":"publisher","first-page":"26931","DOI":"10.1074\/jbc.270.45.26931","volume":"270","author":"DB Constam","year":"1995","unstructured":"Constam DB, Tobler AR, Rensing-Ehl A et al (1995) Puromycin-sensitive Aminopeptidase. J Biol Chem 270:26931\u201326939. https:\/\/doi.org\/10.1074\/jbc.270.45.26931","journal-title":"J Biol Chem"},{"key":"11416_CR40","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1248\/cpb.51.1273","volume":"51","author":"H Kakuta","year":"2003","unstructured":"Kakuta H, Tanatani A, Nagasawa K, Hashimoto Y (2003) Specific nonpeptide inhibitors of puromycin-sensitive aminopeptidase with a 2,4(1H,3H)-quinazolinedione skeleton. Chem Pharm Bull (Tokyo) 51:1273\u20131282. https:\/\/doi.org\/10.1248\/cpb.51.1273","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"11416_CR41","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bmc.2004.10.053","volume":"13","author":"D Carrico","year":"2005","unstructured":"Carrico D, Blaskovich MA, Bucher CJ et al (2005) Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I. Bioorg Med Chem 13:677\u2013688. https:\/\/doi.org\/10.1016\/j.bmc.2004.10.053","journal-title":"Bioorg Med Chem"},{"key":"11416_CR42","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1172\/JCI32108","volume":"117","author":"MR Philips","year":"2007","unstructured":"Philips MR, Cox AD (2007) Geranylgeranyltransferase I as a target for anti-cancer drugs. J Clin Invest 117:1223\u20131225. https:\/\/doi.org\/10.1172\/JCI32108","journal-title":"J Clin Invest"},{"key":"11416_CR43","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ejmech.2015.08.024","volume":"102","author":"G Sociali","year":"2015","unstructured":"Sociali G, Galeno L, Parenti MD et al (2015) Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics. Eur J Med Chem 102:530\u2013539. https:\/\/doi.org\/10.1016\/j.ejmech.2015.08.024","journal-title":"Eur J Med Chem"},{"key":"11416_CR44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-020-01623-w","volume":"39","author":"J Yang","year":"2020","unstructured":"Yang J, Li Y, Zhang Y et al (2020) Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K\/Akt signaling. J Exp Clin Cancer Res 39:142. https:\/\/doi.org\/10.1186\/s13046-020-01623-w","journal-title":"J Exp Clin Cancer Res"},{"key":"11416_CR45","doi-asserted-by":"publisher","first-page":"40924","DOI":"10.1074\/jbc.M112.405837","volume":"287","author":"I Bauer","year":"2012","unstructured":"Bauer I, Grozio A, Lasigli\u00e8 D et al (2012) The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem 287:40924\u201340937. https:\/\/doi.org\/10.1074\/jbc.M112.405837","journal-title":"J Biol Chem"},{"key":"11416_CR46","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-1638","volume":"22","author":"L-K Ran","year":"2016","unstructured":"Ran L-K, Chen Y, Zhang Z-Z et al (2016) SIRT6 overexpression potentiates apoptosis evasion in hepatocellular carcinoma via BCL2-associated X protein-dependent apoptotic pathway. Clin Cancer Res 22:3372\u20133382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1638","journal-title":"Clin Cancer Res"},{"key":"11416_CR47","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/j.celrep.2016.08.006","volume":"16","author":"M Van\u00a0Meter","year":"2016","unstructured":"Van\u00a0Meter M, Simon M, Tombline G et al (2016) JNK phosphorylates SIRT6 to stimulate DNA double-strand break repair in response to oxidative stress by recruiting PARP1 to DNA breaks. Cell Rep 16:2641\u20132650. https:\/\/doi.org\/10.1016\/j.celrep.2016.08.006","journal-title":"Cell Rep"},{"key":"11416_CR48","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.18632\/oncotarget.12157","volume":"8","author":"X Ye","year":"2017","unstructured":"Ye X, Li M, Hou T et al (2017) Sirtuins in glucose and lipid metabolism. Oncotarget 8:1845\u20131859. https:\/\/doi.org\/10.18632\/oncotarget.12157","journal-title":"Oncotarget"},{"key":"11416_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/carcin\/bgv167","volume":"37","author":"B Lerrer","year":"2016","unstructured":"Lerrer B, Gertler AA, Cohen HY (2016) The complex role of SIRT6 in carcinogenesis. Carcinogenesis 37:108\u2013118. https:\/\/doi.org\/10.1093\/carcin\/bgv167","journal-title":"Carcinogenesis"},{"key":"11416_CR50","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.016287","author":"BMM Zwaans","year":"2014","unstructured":"Zwaans BMM, Lombard DB (2014) Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming. Dis Model Mech. https:\/\/doi.org\/10.1242\/dmm.016287","journal-title":"Dis Model Mech"},{"key":"11416_CR51","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/jhet.3889","volume":"57","author":"AH Abdelmonsef","year":"2020","unstructured":"Abdelmonsef AH, Mosallam AM (2020) Synthesis, in vitro biological evaluation and in silico docking studies of new quinazolin-2,4-dione analogues as possible anticarcinoma agents. J Heterocycl Chem 57:1637\u20131654. https:\/\/doi.org\/10.1002\/jhet.3889","journal-title":"J Heterocycl Chem"},{"key":"11416_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/7763545","volume":"2022","author":"MA Alassaf","year":"2022","unstructured":"Alassaf MA, Selim KB, Nasr MNA (2022) Synthesis and biological evaluation of 2,4-diaminoquinazolines as potential antitumor agents. J Chem 2022:1\u20136. https:\/\/doi.org\/10.1155\/2022\/7763545","journal-title":"J Chem"},{"key":"11416_CR53","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/ijms19020408","volume":"19","author":"S Ihmaid","year":"2018","unstructured":"Ihmaid S, Ahmed H, Zayed M (2018) The design and development of potent small molecules as anticancer agents targeting EGFR TK and tubulin polymerization. Int J Mol Sci 19:408. https:\/\/doi.org\/10.3390\/ijms19020408","journal-title":"Int J Mol Sci"},{"key":"11416_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061731","volume":"19","author":"MF Zayed","year":"2018","unstructured":"Zayed MF, Ahmed S, Ihmaid S et al (2018) Design, synthesis, cytotoxic evaluation and molecular docking of new fluoroquinazolinones as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects. Int J Mol Sci 19:1731. https:\/\/doi.org\/10.3390\/ijms19061731","journal-title":"Int J Mol Sci"},{"key":"11416_CR55","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3390\/molecules23071699","volume":"23","author":"MF Zayed","year":"2018","unstructured":"Zayed MF, Rateb HS, Ahmed S et al (2018) Quinazolinone-amino acid hybrids as dual inhibitors of EGFR kinase and tubulin polymerization. Molecules 23:1699. https:\/\/doi.org\/10.3390\/molecules23071699","journal-title":"Molecules"},{"key":"11416_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201700166","author":"IE G\u0142owacka","year":"2017","unstructured":"G\u0142owacka IE, Andrei G, Schols D et al (2017) Design, synthesis, and the biological evaluation of a new series of acyclic 1,2,3\u2010triazole nucleosides. Arch Pharm (Weinheim). https:\/\/doi.org\/10.1002\/ardp.201700166","journal-title":"Arch Pharm (Weinheim)"},{"key":"11416_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105518","volume":"209","author":"IE G\u0142owacka","year":"2023","unstructured":"G\u0142owacka IE, Gawron K, Piotrowska DG et al (2023) Design and synthesis of a new series of hybrids of functionalised N1-[(1H-1,2,3-triazol-4-yl)methyl]quinazoline-2,4-dione with antiviral activity against Respiratory Syncytial Virus. Antivir Res 209:105518. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105518","journal-title":"Antivir Res"},{"key":"11416_CR58","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejmech.2016.10.002","volume":"126","author":"DG Piotrowska","year":"2017","unstructured":"Piotrowska DG, Andrei G, Schols D et al (2017) Synthesis, anti-varicella-zoster virus and anti-cytomegalovirus activity of quinazoline-2,4-diones containing isoxazolidine and phosphonate substructures. Eur J Med Chem 126:84\u2013100. https:\/\/doi.org\/10.1016\/j.ejmech.2016.10.002","journal-title":"Eur J Med Chem"},{"key":"11416_CR59","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.3390\/molecules27196526","volume":"27","author":"M \u0141ysakowska","year":"2022","unstructured":"\u0141ysakowska M, G\u0142owacka IE, Andrei G et al (2022) Design, synthesis, anti-varicella-zoster and antimicrobial activity of (isoxazolidin-3-yl)phosphonate conjugates of N1-functionalised quinazoline-2,4-diones. Molecules 27:6526. https:\/\/doi.org\/10.3390\/molecules27196526","journal-title":"Molecules"},{"key":"11416_CR60","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1016\/j.bmcl.2016.09.071","volume":"26","author":"D Kang","year":"2016","unstructured":"Kang D, Zhang H, Zhou Z et al (2016) First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via \u2018privileged scaffold\u2019 refining approach. Bioorg Med Chem Lett 26:5182\u20135186. https:\/\/doi.org\/10.1016\/j.bmcl.2016.09.071","journal-title":"Bioorg Med Chem Lett"},{"key":"11416_CR61","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11030-020-10141-y","volume":"25","author":"OV Andreeva","year":"2021","unstructured":"Andreeva OV, Garifullin BF, Zarubaev VV et al (2021) Synthesis of 1,2,3-triazolyl nucleoside analogues and their antiviral activity. Mol Divers 25:473\u2013490. https:\/\/doi.org\/10.1007\/s11030-020-10141-y","journal-title":"Mol Divers"},{"key":"11416_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112706","volume":"206","author":"G Zhang","year":"2020","unstructured":"Zhang G, Wang M, Zhao J et al (2020) Design, synthesis and in vitro anti-influenza A virus evaluation of novel quinazoline derivatives containing S-acetamide and NH-acetamide moieties at C-4. Eur J Med Chem 206:112706. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112706","journal-title":"Eur J Med Chem"},{"key":"11416_CR63","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1016\/j.bmc.2019.07.011","volume":"27","author":"P Gao","year":"2019","unstructured":"Gao P, Cheng X, Sun L et al (2019) Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase. Bioorg Med Chem 27:3836\u20133845. https:\/\/doi.org\/10.1016\/j.bmc.2019.07.011","journal-title":"Bioorg Med Chem"},{"key":"11416_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23115930","volume":"23","author":"Y Cao","year":"2022","unstructured":"Cao Y, Aimaiti A, Zhu Z et al (2022) Discovery of novel 3-hydroxyquinazoline-2,4(1H,3H)-dione derivatives: a series of metal ion chelators with potent anti-HCV activities. Int J Mol Sci 23:5930. https:\/\/doi.org\/10.3390\/ijms23115930","journal-title":"Int J Mol Sci"},{"key":"11416_CR65","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1016\/j.bmc.2014.04.042","volume":"22","author":"Q Ji","year":"2014","unstructured":"Ji Q, Yang D, Wang X et al (2014) Design, synthesis and evaluation of novel quinazoline-2,4-dione derivatives as chitin synthase inhibitors and antifungal agents. Bioorg Med Chem 22:3405\u20133413. https:\/\/doi.org\/10.1016\/j.bmc.2014.04.042","journal-title":"Bioorg Med Chem"},{"key":"11416_CR66","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ejmech.2018.05.001","volume":"152","author":"NA Noureldin","year":"2018","unstructured":"Noureldin NA, Kothayer H, Lashine E-SM et al (2018) Design, synthesis and biological evaluation of novel quinazoline-2,4-diones conjugated with different amino acids as potential chitin synthase inhibitors. Eur J Med Chem 152:560\u2013569. https:\/\/doi.org\/10.1016\/j.ejmech.2018.05.001","journal-title":"Eur J Med Chem"},{"key":"11416_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/284947","volume":"2012","author":"MA Hassan","year":"2012","unstructured":"Hassan MA, Younes AMM, Taha MM, Abdel-Monsef A (2012) Synthesis and reactions of 3-(2-chloromethyl-carbonylamino)tetrachloroquinazolin-2,4-dione. Org Chem Int 2012:1\u20134. https:\/\/doi.org\/10.1155\/2012\/284947","journal-title":"Org Chem Int"},{"key":"11416_CR68","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.3390\/molecules27123853","volume":"27","author":"NM Boshta","year":"2022","unstructured":"Boshta NM, El-Essawy FA, Alshammari MB et al (2022) Discovery of quinazoline-2,4(1H,3H)-dione derivatives as potential antibacterial agent: design, synthesis, and their antibacterial activity. Molecules 27:3853. https:\/\/doi.org\/10.3390\/molecules27123853","journal-title":"Molecules"},{"key":"11416_CR69","doi-asserted-by":"publisher","DOI":"10.1177\/1176934319897596","author":"M El-Naggar","year":"2020","unstructured":"El-Naggar M, Mohamed ME, Mosallam AM et al (2020) Synthesis, characterization, antibacterial activity, and computer-aided design of novel quinazolin-2,4-dione derivatives as potential inhibitors against Vibrio cholerae. Evol Bioinform Online. https:\/\/doi.org\/10.1177\/1176934319897596","journal-title":"Evol Bioinform Online"},{"key":"11416_CR70","doi-asserted-by":"publisher","first-page":"17158","DOI":"10.1039\/D4RA02960G","volume":"14","author":"AOA Ibrahim","year":"2024","unstructured":"Ibrahim AOA, Hassan A, Mosallam AM et al (2024) New quinazolin-2,4-dione derivatives incorporating acylthiourea, pyrazole and\/or oxazole moieties as antibacterial agents via DNA gyrase inhibition. RSC Adv 14:17158\u201317169. https:\/\/doi.org\/10.1039\/D4RA02960G","journal-title":"RSC Adv"},{"key":"11416_CR71","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1021\/jm500039e","volume":"57","author":"KS Van Horn","year":"2014","unstructured":"Van Horn KS, Burda WN, Fleeman R et al (2014) Antibacterial activity of a series of N 2, N 4 -disubstituted quinazoline-2,4-diamines. J Med Chem 57:3075\u20133093. https:\/\/doi.org\/10.1021\/jm500039e","journal-title":"J Med Chem"},{"key":"11416_CR72","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1128\/AAC.01321-06","volume":"51","author":"MD Huband","year":"2007","unstructured":"Huband MD, Cohen MA, Zurack M et al (2007) In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase\/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob Agents Chemother 51:1191\u20131201. https:\/\/doi.org\/10.1128\/AAC.01321-06","journal-title":"Antimicrob Agents Chemother"},{"key":"11416_CR73","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1021\/cb400592n","volume":"8","author":"KJ Aldred","year":"2013","unstructured":"Aldred KJ, Schwanz HA, Li G et al (2013) Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. ACS Chem Biol 8:2660\u20132668. https:\/\/doi.org\/10.1021\/cb400592n","journal-title":"ACS Chem Biol"},{"key":"11416_CR74","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.bmcl.2006.12.005","volume":"17","author":"TP Tran","year":"2007","unstructured":"Tran TP, Ellsworth EL, Sanchez JP et al (2007) Structure\u2013activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors. Bioorg Med Chem Lett 17:1312\u20131320. https:\/\/doi.org\/10.1016\/j.bmcl.2006.12.005","journal-title":"Bioorg Med Chem Lett"},{"key":"11416_CR75","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1016\/j.bmcl.2008.07.117","volume":"18","author":"KM Hutchings","year":"2008","unstructured":"Hutchings KM, Tran TP, Ellsworth EL et al (2008) Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones. Bioorg Med Chem Lett 18:5087\u20135090. https:\/\/doi.org\/10.1016\/j.bmcl.2008.07.117","journal-title":"Bioorg Med Chem Lett"},{"key":"11416_CR76","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.saa.2013.03.064","volume":"110","author":"MK Prashanth","year":"2013","unstructured":"Prashanth MK, Madaiah M, Revanasiddappa HD, Veeresh B (2013) Synthesis, anticonvulsant, antioxidant and binding interaction of novel N-substituted methylquinazoline-2,4(1H,3H)-dione derivatives to bovine serum albumin: a structure\u2013activity relationship study. Spectrochim Acta A Mol Biomol Spectrosc 110:324\u2013332. https:\/\/doi.org\/10.1016\/j.saa.2013.03.064","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"11416_CR77","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ardp.201600024","volume":"349","author":"HN Deepakumari","year":"2016","unstructured":"Deepakumari HN, Jayanna BK, Prashanth MK et al (2016) Synthesis and anticonvulsant activity of N -(substituted)-1-methyl-2,4-dioxo-1,2-dihydroquinazoline-3(4 H )-carboxamides. Arch Pharm Weinheim 349:566\u2013571. https:\/\/doi.org\/10.1002\/ardp.201600024","journal-title":"Arch Pharm Weinheim"},{"key":"11416_CR78","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejmech.2019.06.085","volume":"180","author":"WM El Kayal","year":"2019","unstructured":"El Kayal WM, Shtrygol SY, Zalevskyi SV et al (2019) Synthesis, in\u00a0vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide. Eur J Med Chem 180:134\u2013142. https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.085","journal-title":"Eur J Med Chem"},{"key":"11416_CR79","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/1521-4184(20008)333:8<261::AID-ARDP261>3.0.CO;2-O","volume":"333","author":"CO Usifoh","year":"2000","unstructured":"Usifoh CO, Scriba GKE (2000) Synthesis and anticonvulsant activity of acetylenic quinazolinone derivatives. Arch Pharm (Weinheim) 333:261\u2013266. https:\/\/doi.org\/10.1002\/1521-4184(20008)333:8%3c261::AID-ARDP261%3e3.0.CO;2-O","journal-title":"Arch Pharm (Weinheim)"},{"key":"11416_CR80","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ejmech.2012.05.036","volume":"54","author":"V Colotta","year":"2012","unstructured":"Colotta V, Lenzi O, Catarzi D et al (2012) 3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies. Eur J Med Chem 54:470\u2013482. https:\/\/doi.org\/10.1016\/j.ejmech.2012.05.036","journal-title":"Eur J Med Chem"},{"key":"11416_CR81","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/biomedicines11030783","volume":"11","author":"T-S Chen","year":"2023","unstructured":"Chen T-S, Huang T-H, Lai M-C, Huang C-W (2023) The role of glutamate receptors in epilepsy. Biomedicines 11:783. https:\/\/doi.org\/10.3390\/biomedicines11030783","journal-title":"Biomedicines"},{"key":"11416_CR82","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1016\/j.bmcl.2011.04.017","volume":"21","author":"M Koller","year":"2011","unstructured":"Koller M, Lingenhoehl K, Schmutz M et al (2011) Quinazolinedione sulfonamides: a novel class of competitive AMPA receptor antagonists with oral activity. Bioorg Med Chem Lett 21:3358\u20133361. https:\/\/doi.org\/10.1016\/j.bmcl.2011.04.017","journal-title":"Bioorg Med Chem Lett"},{"key":"11416_CR83","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.bmcl.2011.12.009","volume":"22","author":"D Orain","year":"2012","unstructured":"Orain D, Ofner S, Koller M et al (2012) 6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists. Bioorg Med Chem Lett 22:996\u2013999. https:\/\/doi.org\/10.1016\/j.bmcl.2011.12.009","journal-title":"Bioorg Med Chem Lett"},{"key":"11416_CR84","doi-asserted-by":"publisher","first-page":"24380","DOI":"10.1038\/s41598-021-03722-w","volume":"11","author":"A Spasov","year":"2021","unstructured":"Spasov A, Ozerov A, Vassiliev P et al (2021) Synthesis and multifaceted pharmacological activity of novel quinazoline NHE-1 inhibitors. Sci Rep 11:24380. https:\/\/doi.org\/10.1038\/s41598-021-03722-w","journal-title":"Sci Rep"},{"key":"11416_CR85","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/life12101647","volume":"12","author":"A Spasov","year":"2022","unstructured":"Spasov A, Ozerov A, Kosolapov V et al (2022) Guanidine derivatives of quinazoline-2,4(1H,3H)-dione as NHE-1 inhibitors and anti-inflammatory agents. Life 12:1647. https:\/\/doi.org\/10.3390\/life12101647","journal-title":"Life"},{"key":"11416_CR86","doi-asserted-by":"publisher","first-page":"7717","DOI":"10.1016\/j.bmc.2015.11.016","volume":"23","author":"N-C Cho","year":"2015","unstructured":"Cho N-C, Cha JH, Kim H et al (2015) Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists. Bioorg Med Chem 23:7717\u20137727. https:\/\/doi.org\/10.1016\/j.bmc.2015.11.016","journal-title":"Bioorg Med Chem"},{"key":"11416_CR87","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bmc.2017.12.039","volume":"26","author":"Y Fukase","year":"2018","unstructured":"Fukase Y, Sato A, Tomata Y et al (2018) Identification of novel quinazolinedione derivatives as ROR\u03b3t inverse agonist. Bioorg Med Chem 26:721\u2013736. https:\/\/doi.org\/10.1016\/j.bmc.2017.12.039","journal-title":"Bioorg Med Chem"},{"key":"11416_CR88","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/00498257509056092","volume":"5","author":"R Kodama","year":"1975","unstructured":"Kodama R, Yano T, Furukawa K et al (1975) Metabolism of 1-(3-Trifluoromethylphenyl)- 3-(2-hydroxyethyl) quinazoline-2,4(1 H ,3 H )-dione(H-88): I. species differences in metabolism. Xenobiotica 5:39\u201348. https:\/\/doi.org\/10.3109\/00498257509056092","journal-title":"Xenobiotica"},{"key":"11416_CR89","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/bmj.284.6315.537","volume":"284","author":"GJ Wenting","year":"1982","unstructured":"Wenting GJ, Woittiez AJ et al (1982) Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. BMJ 284:537\u2013539. https:\/\/doi.org\/10.1136\/bmj.284.6315.537","journal-title":"BMJ"},{"key":"11416_CR90","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1365-2125.1983.tb04974.x","volume":"16","author":"T Hedner","year":"1983","unstructured":"Hedner T, Persson B, Berglund G (1983) Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension. Br J Clin Pharmacol 16:121\u2013125. https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb04974.x","journal-title":"Br J Clin Pharmacol"},{"key":"11416_CR91","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0014-2999(95)00074-U","volume":"277","author":"R Villalobos-Molina","year":"1995","unstructured":"Villalobos-Molina R, Ibarra M, Hong E (1995) The 5-HT2 receptor antagonist, pelanserin, inhibits \u03b11-adrenoceptor-mediated vasoconstriction in vitro. Eur J Pharmacol 277:181\u2013185. https:\/\/doi.org\/10.1016\/0014-2999(95)00074-U","journal-title":"Eur J Pharmacol"},{"key":"11416_CR92","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/17518250802331181","volume":"1","author":"YP Patil","year":"2008","unstructured":"Patil YP, Tambade PJ, Jagtap SR, Bhanage BM (2008) Cesium carbonate catalyzed efficient synthesis of quinazoline-2,4(1 H,3 H )-diones using carbon dioxide and 2-aminobenzonitriles. Green Chem Lett Rev 1:127\u2013132. https:\/\/doi.org\/10.1080\/17518250802331181","journal-title":"Green Chem Lett Rev"},{"key":"11416_CR93","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1021\/jm00395a016","volume":"30","author":"WB Wright","year":"1987","unstructured":"Wright WB, Tomcufcik AS, Chan PS et al (1987) Thromboxane synthetase inhibitors and antihypertensive agents. 4. N-[(1H-imidazol-1-yl)alkyl] derivatives of quinazoline-2,4(1H,3H)-diones, quinazolin-4(3H)-ones, and 1,2,3-benzotriazin-4(3H)-ones. J Med Chem 30:2277\u20132283. https:\/\/doi.org\/10.1021\/jm00395a016","journal-title":"J Med Chem"},{"key":"11416_CR94","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1021\/jm00198a024","volume":"22","author":"HJ Havera","year":"1979","unstructured":"Havera HJ (1979) Derivatives of 1,3-disubstituted 2,4(1H,3H)-quinazolinediones as possible peripheral vasodilators or antihypertensive agents. J Med Chem 22:1548\u20131550. https:\/\/doi.org\/10.1021\/jm00198a024","journal-title":"J Med Chem"},{"key":"11416_CR95","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1254\/jjp.35.19","volume":"35","author":"S Ishikawa","year":"1984","unstructured":"Ishikawa S (1984) Effects of a new Alphai-Adrenoceptor blocking agent, 3-[2-[4-(2-Methoxyphenyl)-1-Piperazinyl]Ethyl]-(1H,3H)-Quinazoline-2,4-Dione Monohydrochloride (SGB1534), on electrical and mechanical properties of Guinea-pig Mesenteric Artery. Jpn J Pharmacol 35:19\u201325. https:\/\/doi.org\/10.1254\/jjp.35.19","journal-title":"Jpn J Pharmacol"},{"key":"11416_CR96","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/jm00330a017","volume":"8","author":"S Hayao","year":"1965","unstructured":"Hayao S, Havera HJ, Strycker WG et al (1965) New sedative and hypotensive 3-substituted 2,4(1H,3H)-quinazolinediones. J Med Chem 8:807\u2013811. https:\/\/doi.org\/10.1021\/jm00330a017","journal-title":"J Med Chem"},{"key":"11416_CR97","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1021\/jm5000408","volume":"57","author":"KS Van Horn","year":"2014","unstructured":"Van Horn KS, Zhu X, Pandharkar T et al (2014) Antileishmanial activity of a series of N 2, N 4 -disubstituted quinazoline-2,4-diamines. J Med Chem 57:5141\u20135156. https:\/\/doi.org\/10.1021\/jm5000408","journal-title":"J Med Chem"},{"key":"11416_CR98","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s11030-016-9693-8","volume":"20","author":"E Enciso","year":"2016","unstructured":"Enciso E, Sarmiento-S\u00e1nchez JI, L\u00f3pez-Moreno HS et al (2016) Synthesis of new quinazolin-2,4-diones as anti-Leishmania mexicana agents. Mol Divers 20:821\u2013828. https:\/\/doi.org\/10.1007\/s11030-016-9693-8","journal-title":"Mol Divers"},{"key":"11416_CR99","doi-asserted-by":"publisher","first-page":"M1358","DOI":"10.3390\/M1358","volume":"2022","author":"S Charoensutthivarakul","year":"2022","unstructured":"Charoensutthivarakul S, Lohawittayanan D, Kanjanasirirat P et al (2022) A concise synthesis towards antimalarial quinazolinedione TCMDC-125133 and its anti-proliferative activity against MCF-7. Molbank 2022:M1358. https:\/\/doi.org\/10.3390\/M1358","journal-title":"Molbank"},{"key":"11416_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00105","author":"A Haredi Abdelmonsef","year":"2020","unstructured":"Haredi Abdelmonsef A, Eldeeb Mohamed M, El-Naggar M et al (2020) Novel quinazolin-2,4-dione hybrid molecules as possible inhibitors against malaria: synthesis and in silico molecular docking studies. Front Mol Biosci. https:\/\/doi.org\/10.3389\/fmolb.2020.00105","journal-title":"Front Mol Biosci"},{"key":"11416_CR101","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12039-020-01813-1","volume":"132","author":"L Santos-Ballardo","year":"2020","unstructured":"Santos-Ballardo L, Garc\u00eda-P\u00e1ez F, Picos-Corrales LA et al (2020) Synthesis, biological evaluation and molecular docking of 3-substituted quinazoline-2,4(1H, 3H)-diones. J Chem Sci 132:100. https:\/\/doi.org\/10.1007\/s12039-020-01813-1","journal-title":"J Chem Sci"},{"key":"11416_CR102","doi-asserted-by":"publisher","first-page":"7783","DOI":"10.1021\/acs.jmedchem.6b00041","volume":"59","author":"H Duan","year":"2016","unstructured":"Duan H, Lee JW, Moon SW et al (2016) Discovery, synthesis, and evaluation of 2,4-diaminoquinazolines as a novel class of pancreatic \u03b2-cell-protective agents against endoplasmic reticulum (ER) stress. J Med Chem 59:7783\u20137800. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00041","journal-title":"J Med Chem"},{"key":"11416_CR103","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1016\/j.ejmech.2010.02.038","volume":"45","author":"IM El-Deeb","year":"2010","unstructured":"El-Deeb IM, Bayoumi SM, El-Sherbeny MA, Abdel-Aziz AA-M (2010) Synthesis and antitumor evaluation of novel cyclic arylsulfonylureas: ADME-T and pharmacophore prediction. Eur J Med Chem 45:2516\u20132530. https:\/\/doi.org\/10.1016\/j.ejmech.2010.02.038","journal-title":"Eur J Med Chem"},{"key":"11416_CR104","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1039\/C8OB00286J","volume":"16","author":"J Zhou","year":"2018","unstructured":"Zhou J, Ji M, Yao H et al (2018) Discovery of quinazoline-2,4(1 H,3 H )-dione derivatives as novel PARP-1\/2 inhibitors: design, synthesis and their antitumor activity. Org Biomol Chem 16:3189\u20133202. https:\/\/doi.org\/10.1039\/C8OB00286J","journal-title":"Org Biomol Chem"},{"key":"11416_CR105","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.bmc.2014.12.071","volume":"23","author":"H Yao","year":"2015","unstructured":"Yao H, Ji M, Zhu Z et al (2015) Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors. Bioorg Med Chem 23:681\u2013693. https:\/\/doi.org\/10.1016\/j.bmc.2014.12.071","journal-title":"Bioorg Med Chem"},{"key":"11416_CR106","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1021\/acs.jmedchem.8b01590","volume":"62","author":"C-W Yu","year":"2019","unstructured":"Yu C-W, Hung P-Y, Yang H-T et al (2019) Quinazolin-2,4-dione-based hydroxamic acids as selective histone deacetylase-6 inhibitors for treatment of non-small cell lung cancer. J Med Chem 62:857\u2013874. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01590","journal-title":"J Med Chem"},{"key":"11416_CR107","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202000068","author":"K El-Adl","year":"2020","unstructured":"El-Adl K, El-Helby AA, Sakr H, El-Hddad SSA (2020) Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1 H, 3 H )-dione bearing different moieties as VEGFR-2 inhibitors. Arch Pharm (Weinheim). https:\/\/doi.org\/10.1002\/ardp.202000068","journal-title":"Arch Pharm (Weinheim)"},{"key":"11416_CR108","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2189578","author":"A Hassan","year":"2023","unstructured":"Hassan A, Mubarak FAF, Shehadi IA et al (2023) Design and biological evaluation of 3-substituted quinazoline-2,4(1 H ,3 H )-dione derivatives as dual c-Met\/VEGFR-2-TK inhibitors. J Enzyme Inhib Med Chem. https:\/\/doi.org\/10.1080\/14756366.2023.2189578","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11416_CR109","doi-asserted-by":"publisher","first-page":"18567","DOI":"10.1038\/s41598-023-45687-y","volume":"13","author":"A Hassan","year":"2023","unstructured":"Hassan A, Mosallam AM, Ibrahim AOA et al (2023) Novel 3-phenylquinazolin-2,4(1H,3H)-diones as dual VEGFR-2\/c-Met-TK inhibitors: design, synthesis, and biological evaluation. Sci Rep 13:18567. https:\/\/doi.org\/10.1038\/s41598-023-45687-y","journal-title":"Sci Rep"},{"key":"11416_CR110","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1021\/acs.jmedchem.7b00766","volume":"60","author":"M Falsini","year":"2017","unstructured":"Falsini M, Squarcialupi L, Catarzi D et al (2017) 3-Hydroxy-1 H -quinazoline-2,4-dione as a new scaffold to develop potent and selective inhibitors of the tumor-associated carbonic anhydrases IX and XII. J Med Chem 60:6428\u20136439. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00766","journal-title":"J Med Chem"},{"key":"11416_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29133050","volume":"29","author":"M \u0141ysakowska","year":"2024","unstructured":"\u0141ysakowska M, G\u0142owacka IE, Honkisz-Orzechowska E et al (2024) New 3-(Dibenzyloxyphosphoryl)isoxazolidine conjugates of N1-benzylated quinazoline-2,4-diones as potential cytotoxic agents against cancer cell lines. Molecules 29:3050. https:\/\/doi.org\/10.3390\/molecules29133050","journal-title":"Molecules"},{"key":"11416_CR112","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1016\/j.bmc.2017.05.052","volume":"25","author":"H Zhao","year":"2017","unstructured":"Zhao H, Ji M, Cui G et al (2017) Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors. Bioorg Med Chem 25:4045\u20134054. https:\/\/doi.org\/10.1016\/j.bmc.2017.05.052","journal-title":"Bioorg Med Chem"},{"key":"11416_CR113","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/cjoc.201700280","volume":"35","author":"G Shi","year":"2017","unstructured":"Shi G, He X, Shang Y et al (2017) Oxidative rearrangement of isatins with arylamines using <scp>H2 O2 <\/scp>as oxidant: a facile synthesis of quinazoline-2,4-diones and evaluation of their antibacterial activity. Chin J Chem 35:1835\u20131843. https:\/\/doi.org\/10.1002\/cjoc.201700280","journal-title":"Chin J Chem"},{"key":"11416_CR114","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00044-013-0813-z","volume":"23","author":"Q-G Ji","year":"2014","unstructured":"Ji Q-G, Yang D, Deng Q et al (2014) Design, synthesis, and evaluation of novel 1-methyl-3-substituted quinazoline-2,4-dione derivatives as antimicrobial agents. Med Chem Res 23:2169\u20132177. https:\/\/doi.org\/10.1007\/s00044-013-0813-z","journal-title":"Med Chem Res"},{"key":"11416_CR115","doi-asserted-by":"publisher","first-page":"52227","DOI":"10.1039\/C7RA10352B","volume":"7","author":"Z Jiang","year":"2017","unstructured":"Jiang Z, Hong WD, Cui X et al (2017) Synthesis and structure\u2013activity relationship of N 4 -benzylamine-N 2 -isopropyl-quinazoline-2,4-diamines derivatives as potential antibacterial agents. RSC Adv 7:52227\u201352237. https:\/\/doi.org\/10.1039\/C7RA10352B","journal-title":"RSC Adv"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11416-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11416-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11416-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:02:25Z","timestamp":1791266545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11416-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":115,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11416"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11416-y","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}